Post-Orgasmic Illness Syndrome Successfully Treated with Omalizumab: A Case Report

Area of Science:

• Reproductive medicine
• Immunology
• Neurology

Background:

• Post-orgasmic illness syndrome (POIS) is a rare condition characterized by debilitating symptoms following ejaculation.
• The exact pathophysiology of POIS remains elusive, though hypersensitivity to semen or seminal fluid is a leading hypothesis.
• POIS significantly impairs patients' quality of life due to its recurrent and severe nature.

Observation:

• A patient diagnosed with Post-orgasmic illness syndrome (POIS) presented with severe post-ejaculatory symptoms.
• Standard treatments for POIS have historically yielded limited success in managing symptoms.
• The patient's condition was refractory to conventional therapeutic approaches.

Findings:

• The patient was treated with omalizumab, an anti-immunoglobulin E antibody.
• Following omalizumab administration, the patient experienced a significant reduction in POIS symptoms.
• This response suggests a potential role for IgE-mediated mechanisms in POIS pathogenesis.

Implications:

• Omalizumab represents a novel therapeutic avenue for managing Post-orgasmic illness syndrome.
• Further research is warranted to elucidate the immunological underpinnings of POIS.
• This case highlights the importance of considering targeted immunotherapies for rare disorders like POIS.